Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/109281
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Guo, B | - |
dc.creator | Zhang, S | - |
dc.creator | Xu, L | - |
dc.creator | Sun, J | - |
dc.creator | Chan, WL | - |
dc.creator | Zheng, P | - |
dc.creator | Zhang, J | - |
dc.creator | Zhang, L | - |
dc.date.accessioned | 2024-10-03T08:17:40Z | - |
dc.date.available | 2024-10-03T08:17:40Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/109281 | - |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Research Foundation | en_US |
dc.rights | © 2023 Guo, Zhang, Xu, Sun, Chan, Zheng, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | en_US |
dc.rights | The following publication Guo B, Zhang S, Xu L, Sun J, Chan W-L, Zheng P, Zhang J and Zhang L (2023) Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas: a systematic review and meta-analysis. Front. Immunol. 14:966696 is available at https://doi.org/10.3389/fimmu.2023.966696. | en_US |
dc.subject | Glioblastoma | en_US |
dc.subject | Glioma | en_US |
dc.subject | High-grade | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Meta-analysis | en_US |
dc.subject | Radiotherapy | en_US |
dc.subject | Standard of care | en_US |
dc.subject | Temozolomide | en_US |
dc.title | Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas : a systematic review and meta-analysis | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 14 | - |
dc.identifier.doi | 10.3389/fimmu.2023.966696 | - |
dcterms.abstract | Background: Malignant glioma is the most common intracranial malignant tumor with the highest mortality. In the era of immunotherapy, it is important to determine what type of immunotherapy provides the best chance of survival. | - |
dcterms.abstract | Method: Here, the efficacy and safety of immunotherapy in high-grade glioma (HGG) were evaluated by systematic review and meta-analysis. The differences between various types of immunotherapy were explored. Retrieved hits were screened for inclusion in 2,317 articles. We extracted the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) as two key outcomes for examining the efficacy of immunotherapy. We also analyzed data on the reported corresponding adverse events to assess the safety of immunotherapy. This study was registered with PROSPERO (CRD42019112356). | - |
dcterms.abstract | Results: We included a total of 1,271 patients, of which 524 received a combination of immunotherapy and standard of care (SOC), while 747 received SOC alone. We found that immunotherapy extended the OS (HR = 0.74; 95% confidence interval [CI], 0.56−0.99; Z = −2.00, P = 0.0458 < 0.05) and PFS (HR = 0.67; 95% CI, 0.45−0.99; Z = −1.99, P = 0.0466 < 0.05), although certain adverse events occurred (proportion = 0.0773, 95% CI, 0.0589-0.1014). Our data have demonstrated the efficacy of the dendritic cell (DC) vaccine in prolonging the OS (HR = 0.38; 95% CI, 0.21−0.68; Z = −3.23; P = 0.0012 < 0.05) of glioma patients. Oncolytic viral therapy (VT) only extended patient survival in a subgroup analysis (HR = 0.60; 95% CI, 0.45−0.80; Z = −3.53; P = 0.0004 < 0.05). By contrast, immunopotentiation (IP) did not prolong OS (HR = 0.69; 95% CI, 0.50−0.96; Z = −2.23; P = 0.0256). | - |
dcterms.abstract | Conclusion: Thus, DC vaccination significantly prolonged the OS of HGG patients, however, the efficacy of VT and IP should be explored in further studies. All the therapeutic schemes evaluated were associated with certain side effects. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Frontiers in immunology, 2023, v. 14, 966696 | - |
dcterms.isPartOf | Frontiers in immunology | - |
dcterms.issued | 2023 | - |
dc.identifier.scopus | 2-s2.0-85165162530 | - |
dc.identifier.eissn | 1664-3224 | - |
dc.identifier.artn | 966696 | - |
dc.description.validate | 202410 bcch | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | National Natural Science Foundation of China; Jilin Province lnnovation and Entrepreneurship Talent Funding Project; Research Fund of Jilin Provincial Science and Technology Department; China-Japan Union Hospital and College of Basic Medical Sciences, Jilin University Union Proiect; Hong Kong Polytechnic University Startup Fund for RAPs under the Strategic Hiring Scheme | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-966696.pdf | 2.82 MB | Adobe PDF | View/Open |
Page views
18
Citations as of Nov 24, 2024
Downloads
8
Citations as of Nov 24, 2024
SCOPUSTM
Citations
2
Citations as of Nov 21, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.